Expansion of non-invasive prenatal screening to the screening of 10 types of chromosomal anomalies: a cost-effectiveness analysis.

Soukkhaphone B, Baradaran M, Nguyen BD, et al. BMJ Open. 2023;13(8):e069485. Published 2023 Aug 30. doi:10.1136/bmjopen-2022-069485. Open Access: Learn more

Tags: Health Economics, 2023, Canada, RAAs, CNVs

  • Based on results of this simulation study, the most effective and most cost-effective option in almost all screening strategies is the one that includes all additional targeted conditions (SCAs, 22q11.2 deletions syndrome, large deletions/duplications >7 Mb and RATs).
  • “The acceptability curves show that at a willingness-to-pay of $C50 000 per one additional case detected, the expansion of NIPS-based methods for the detection of all possible additional conditions has a 90% probability of being cost-effective.”
  • “Conclusion: From an economic perspective, in strategies that use NIPS as a first-tier screening test, expanding the programmes to detect any considered chromosomal anomalies other than the three common trisomies would be cost-effective. However, the potential expansion of prenatal screening programmes also requires consideration of societal issues, including ethical ones.”